Navigation Links
CV Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

- Ranexa(R) net revenue grows 19 percent quarter-over-quarter -

PALO ALTO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the third quarter ended September 30, 2008.

For the quarter ended September 30, 2008, the Company reported a net loss of $25.4 million, or $0.41 per share. This compares to a net loss of $34.2 million, or $0.58 per share, for the same quarter in 2007 and $4.3 million, or $0.07 per share, for the prior quarter ended June 30, 2008. Excluding the impact of the $22.0 million milestone revenue recognized in the quarter ended June 30, 2008, the prior quarter net loss would have been $26.3 million. The milestone payments received in the second quarter of 2008 were $12.0 million from Astellas Pharma U.S. Inc. (Astellas) associated with the U.S. Food and Drug Administration approval for Lexiscan(R) (regadenoson) injection and $10.0 million relating to a milestone payment from TPG-Axon Capital associated with the commercial launch of Lexiscan(R).

For the quarter ended September 30, 2008, the Company recorded $30.3 million of net product sales of Ranexa(R) (ranolazine extended-release tablets) in the U.S., which represents an increase of 19 percent compared to the $25.4 million of net product sales recorded in the prior quarter ended June 30, 2008 and an increase of 65 percent compared to the $18.4 million of net product sales recorded in the same quarter in the prior year.

For the quarter ended September 30, 2008, the Company recorded total revenues of $38.1 million, which consisted of $30.3 million of net product sales of Ranexa, $4.7 million of royalty and license revenue and $3.2 million of collaboration, milestone and other reve
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
2. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
3. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
4. Nile Therapeutics to Present at Two Upcoming Investor Conferences
5. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. United Therapeutics Reports Third Quarter 2008 Financial Results
9. Arete Therapeutics Bolsters Management Team
10. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
11. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... TRIANGLE PARK, N.C. , May 1, 2015  United ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer of ... company,s business at the Deutsche Bank 40 th Annual ... The presentation will take place on Wednesday, May ... accessed via a live webcast on the United Therapeutics website ...
(Date:4/30/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, announced plans to ... 2015 on May 7, 2015 after the close of ... host a conference call at 4:30 p.m. Eastern Time ... financial results. During the conference call, material information concerning ...
(Date:4/30/2015)... San Francisco, CA (PRWEB) April 30, 2015 ... for the first quarter of 2015 were $4.4 million, compared ... The net loss for the first quarter was $8.9 million, ... to a net loss for the same period in 2014, ... share. As of March 31, 2015, cash, cash equivalents and ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... -- Third Wave Technologies , a provider of ... line with market expectations. , ,Third Wave reported total revenue ... or 13 cents per diluted share, for the quarter ended ... and a net loss of $106,000 and zero cents per ...
... Wis . - Customer Potential Management , a ... that its customer relationship management solution has been implemented ... , ,St. John used the CRM solution to promote ... Center, a 15-year partnership with oncologists from both hospitals. ...
... Wis. - Madison Area Technical College is launching ... energy technologies in technical colleges and high schools. The ... and other resources to better prepare qualified technicians to ... ,A $500,000 National Science Foundation (NSF) grant - the ...
Cached Biology Technology:Transition continues to impact Third Wave financials 2
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... of South Florida researchers have identified a genetic biomarker ... and preventing a condition of aging that affects 30 ... In a nine-year study that was a collaboration ... and the National Technical Institute for the Deaf at ...
... fatty acidsfound in foods like wild fish and grass-fed ... the working memory of healthy young adults have not ... of its kind, researchers at the University of Pittsburgh ... improve their working memory even further by increasing their ...
... Researchers report in the journal Developmental Cell ... and regeneration of the intestine in the freshwater planarian ... internal organs after injury is not well understood," said ... Newmark, who led the study. "Planarian flatworms are useful ...
Cached Biology News:USF researchers identify gene mutation linked to old age hearing loss 2Omega-3 intake heightens working memory in healthy young adults 2Omega-3 intake heightens working memory in healthy young adults 3Using planarian flatworms to understand organ regeneration 2
... number is a new product number, ... number. If showing no availability yet, ... number (E6152) or contact customer service ... diam. 11.25 6.40 in. ...
... Analysis of large numbers of samples may ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z35,347-7) ...
Biology Products: